Clinical Trials Logo

Clinical Trial Summary

This is a prospective, single arm, early feasibility study (EFS) designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart failure who require diuresis for the treatment of volume overload.


Clinical Trial Description

This is a prospective, single arm, early feasibility study (EFS) designed to evaluate the safety and device performance of The Reprieve System in the management of patients admitted with signs and symptoms of congestive heart failure who require diuresis for the treatment of volume overload. Subjects will be referred by their physician if he/she feels that the subject could benefit from observed diuresis in a hospital setting.

The device being utilized is called The Reprieve System (The System). By default, The System infuses a volume of hydration fluid equal to the volume of urine output. This is known as matched hydration. In addition, the clinician has the ability to adjust the matched setting such that RenalGuard can infuse hydration fluid to achieve a positive fluid balance (e.g. +100 ml/hr.) or a negative fluid balance (e.g. -100 ml/hr.). The purpose of this balanced fluid replacement is to prevent hypovolemia that may lead to hypotension and vital organ dysfunction, or fluid overload that may lead to shortness of breath in subjects in whom high urine output is desired.

All patients will be treated with The Reprieve System for up to 72-hours, at the investigators discretion. They will be followed for 30 days post discharge. The protocol will enroll up to 40 subjects to develop the clinical algorithm required to optimally and safely perform removal of volume. The study will be conducted in up to 5 sites in the United States. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03866551
Study type Interventional
Source CardioRenal Systems, Inc.
Contact
Status Not yet recruiting
Phase N/A
Start date May 1, 2019
Completion date February 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02788656 - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) N/A
Completed NCT02885636 - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial Phase 3
Completed NCT02252757 - Assess Measurements of Wireless Cardiac Output Device N/A
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Recruiting NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients N/A
Withdrawn NCT00346177 - Stem Cell Study for Patients With Heart Failure Phase 2
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Active, not recruiting NCT01058837 - SCD-HeFT 10 Year Follow-up N/A
Completed NCT00957541 - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device Phase 2
Recruiting NCT01099982 - Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease
Completed NCT00644410 - Autologous Mesenchymal Stromal Cell Therapy in Heart Failure Phase 1/Phase 2
Not yet recruiting NCT00716885 - The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing N/A
Completed NCT03014375 - Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites Phase 1
Completed NCT01857999 - Losartan in Decompensated Heart Failure Phase 4
Active, not recruiting NCT00526253 - To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction Phase 2/Phase 3
Completed NCT00344903 - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort N/A
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2
Recruiting NCT00560339 - Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients? N/A
Active, not recruiting NCT00351390 - Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting. N/A
Completed NCT00752596 - Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient Phase 2